Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634037 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL16692078 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL234271 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7037381 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL887187 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL31400174 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL11441576 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL16283432 | 0.95 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL535583 | 0.95 | HTT (0.74) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL2453444 | 0.94 | HTT (0.65) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911795-B1 | METHOD OF STRENGTHENING NON-KERATINOUS FIBERS, AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2025-10-01 | — | — | EP | claimed |
| CN-113646479-B | Method for strengthening non-keratin fibers and use thereof | 埃斯普投资有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| WO-2025235840-A1 | ECHINOCANDIN-LIKE AND BORON-CONTAINING ECHINOCANDIN COMPOUNDS AND THEIR USE AS AGROCHEMICAL FUNGICIDES | 5METIS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-3911795-B1 | METHOD OF STRENGTHENING NON-KERATINOUS FIBERS, AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-3917926-B1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF | CANWELL BIOTECH LTD (HK) | 2025-10-01 | — | — | EP | disclosed |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-21 | — | — | US | disclosed |
| US-12122772-B2 | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | CANWELL BIOTECH LIMITED (CN) | 2024-10-22 | — | — | US | disclosed |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| US-5652213-A | CYCLIC HEXAPEPTIDE FUNGICIDES, PARASITICIDES | ELI LILLY AND COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1996037510-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0744405-A2 | Cyclic peptide antifungal agents | ELI LILLY AND COMPANY (US) | 1996-11-27 | — | — | EP | disclosed |
| US-4742067-A | Acylalkylaminocarbonyl substituted amino and imino acid compounds | E. R. SQUIBB & SONS, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4621092-A | HYPOTENSIVE, ANALGESIC | E. R. SQUIBB & SONS, INC. (US) | 1986-11-04 | — | — | US | disclosed |
| US-4604402-A | HYPOTENSIVE AGNETS | E. R. SQUIBB & SONS, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0159156-A1 | Hydroxy substituted ureido amino and imino acids | E.R. Squibb & Sons, Inc. (US) | 1985-10-23 | — | — | EP | disclosed |
| EP-0103496-A1 | Acylalkylaminocarbonyl substituted amino and imino acid compounds | E.R. Squibb & Sons, Inc. (US) | 1984-03-21 | — | — | EP | disclosed |
| US-4180565-A | ANTIBACTERIAL AGENTS, ANTIBIOTICS | SCHERING CORPORATION (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | HTT 1159/4885TGM2 494/4885LMNA 2788/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | HTT 112/4885TGM2 2410/4885LMNA 1430/4885 |
| US-12122772-B2 | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | TLR8, TLR7, TLR1 | HTT 4718/4885TGM2 3564/4885LMNA 3434/4885 |
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IRF3, IFNG, STING1 | HTT 4243/4885TGM2 3611/4885LMNA 3804/4885 |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | SARS1, CD14, ACE2 | HTT 1998/4885TGM2 825/4885LMNA 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.